Hyper-CVAD vs. BFM-Like Regimens in Adult Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia: A Single-Center Experience | ||
| SECI Oncology Journal | ||
| Article 2, Volume 9, Issue 2, April 2021, Pages 70-76 | ||
| DOI: 10.21608/secioj.2021.166288 | ||
| Abstract | ||
| Background: ALL (Acute lymphoblastic leukemia) known as one of the diversity group of diseases associated with lymphoblasts proliferation. Innovations in ALL results do have unmet needs in adult patients. Objective: This research was performed at Mansoura University Oncology Center to compare the effects of BFM-like chemotherapy versus hyperCVAD in adult ALL patients. Material and methods: This research was conducted to 77 adult Philadelphia negative ALL patients: 49 males (63.6%) and 28 females (36.4%), mean age of 28 years (range: 16–60). The results in both arms are compared; BFM-like versus hyper-CVAD. Results: Of the 77 patients involved, there were 48 (62.3%) of B-cell ALL, 29 (37.7%) of T-cell ALL. 51 (66.2%) of those received BFM-like chemotherapy, 26 (33.8%) were treated with Hyper-CVAD. The rate of first complete remission (CR) was 90.2% in BFM-like chemotherapy arm versus 73.1% in and hyper-CVAD arm, (p=0.05). Relapse rate was not statistically different in both treatment groups. In terms of the different toxicities, ICU admission rates, and therapy related deaths, both regimens were equivalent. In contrast to hyper-CVAD, patients with BFM- demonstrated significant advantage for overall survival (OS) (median; 28 vs. 12 month p=0.008). Furthermore; younger patients (Conclusions: For young adult ALL patients, BFM-like regimen appears to be suitable. In adult patients ≥30 years, both BFM-like and the hyper-CVAD regimen seems equivalent, safe and effective. | ||
| Keywords | ||
| ALL; BFM-like regimen; hyper-CVAD | ||
|
Supplementary Files
|
||
|
Statistics Article View: 197 |
||
